Frazier Healthcare Partners is a healthcare investment firm for pharmaceuticals, healthcare services, & medical products.
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies. The firm has over $2B under management and has made investments in over 170 healthcare companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations.Frazier’s experienced team takes an active approach to helping build portfolio companies, leveraging the team’s deep domain expertise and expansive network of healthcare executives, advisors, and industry thought leaders. The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors. The firm’s Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Jan 25, 2022
Metagenomi
|
Series B | $175M | Artificial Intelligence | — |
Dec 9, 2020
Rocket Pharmaceuticals
|
Post-IPO Equity | $299M | Biotechnology | — |
Jul 27, 2020
MBX Biosciences
|
Series A | $34.60M | Biotechnology | Yes |
Apr 1, 2020
Aspen Neuroscience
|
Series A | $70M | Biotechnology | — |
Jan 1, 2020
IVERIC bio
|
Post-IPO Equity | — | Biotechnology | — |